TTrialPathMatch Me to Trials
← Back to trials
RecruitingCannabis Use Disorder

A Study of Cannabidiol in Young Adult Cannabis Users

Eligible age

18–25 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The investigators will study the harm-reducing effect of hemp-derived CBD in non-treatment-seeking emerging adults who use cannabis regularly. The study will use a novel naturalistic cannabis administration approach, which examines ecologically valid cannabis use utilizing a mobile lab setting to assess the effects of the cannabis products the participants regularly use. The investigators will recruit a sample of emerging adults, half of whom primarily use flower products and half of whom primarily use concentrate products. Individuals will be randomly assigned to hemp-derived CBD or placebo.

Sponsor: University of Colorado, Denver

You may qualify if…

  • ✓ 1. Ages 18-25
  • ✓ 2. Must have used cannabis flower or concentrates at least five days per week for the past year.
  • ✓ 3. Currently not seeking to cut down or stop cannabis use
  • ✓ 4. At least two symptoms of a DSM-5 cannabis use disorder

You may not qualify if…

  • ✕ 1. Use of any illicit substance besides alcohol, nicotine, or cannabis (e.g., cocaine, opiates, methamphetamine, MDMA, benzodiazepines, or barbiturates) in the past 60 days, as indicated by self-report and urine toxicology screening at the beginning of each study visit.
  • ✕ 2. Alcohol use on 3 or more days per week, and/or \>3 drinks per drinking day in the past 60 days. Participants must also have a breath alcohol level of 0 at the beginning of each study visit.
  • ✕ 3. Daily nicotine use.
  • ✕ 4. Meets DSM-5 diagnostic criteria for a psychotic disorder (e.g., schizophrenia, schizophreniform disorder, schizoaffective disorder), bipolar disorder, major depression with suicidal ideation, or a history of treatment for these disorders.
  • ✕ 5. Current cardiovascular or respiratory disease (e.g., coronary artery disease, severe asthma, chronic obstructive pulmonary disease)
  • ✕ 6. Current use of any psychotropic (e.g., antidepressants, anxiogenics) or hepatotoxic medication.
  • ✕ 7. Current use of anti-epileptic medications (e.g., clobazam, sodium valproate) or medications known to have major interactions with Epidiolex (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, and/or teriflunomide) or a history of seizures.
  • ✕ 8. Current use of strong or moderate CYP3A4 inhibitors or inducers (commonly used examples not captured by other exclusion criteria include protease inhibitors, macrolide antibiotics \[e.g., erythromycin\], azole antifungals \[e.g., ketoconazole\], verapamil, and grapefruit juice).

Where it's recruiting

Colorado

Aurora

Source: ClinicalTrials.gov · NCT06569394 · last updated 2026-05-01

A Study of Cannabidiol in Young Adult Cannabis Users · TrialPath